Cencora, Inc. (COR) Business Profile

What it does

Cencora sources and distributes pharmaceuticals and provides services to healthcare providers and drug manufacturers. It was founded in 2001 and is headquartered in Chesterbrook. Robert P. Mauch is its president and chief executive officer.

The company buys products from manufacturers and supplies healthcare providers, typically serving as their primary source of pharmaceuticals. Its products include brand-name and generic drugs, specialty medicines, over-the-counter healthcare products, and home healthcare supplies and equipment. Customers include hospitals and health systems, retail and mail-order pharmacies, physician practices, clinics and veterinarians.

Cencora also provides services alongside distribution. For providers, these include pharmacy management, inventory management, software and packaging. For manufacturers, they include help with product launches, reimbursement, regulatory affairs, clinical development and transportation. Its logistics operations move specialty products for biopharmaceutical companies.

The business includes services for independent specialty physician practices. Retina Consultants of America and OneOncology are part of its management services organization platform, which helps practices manage clinical and administrative work and supports research. Cencora completed its acquisition of OneOncology in February 2026.

Cencora has also supplied the animal health market, though it has agreed to merge MWI Animal Health with Covetrus. Its international businesses distribute products primarily in Europe and provide commercialization and logistics services across markets.

How it makes money

Cencora earns revenue by distributing pharmaceuticals and healthcare products and by providing services to providers and manufacturers. Distribution involves purchasing products from manufacturers and supplying them to customers; the company also earns money from activities such as logistics, consulting, pharmacy services and specialty practice management.

Consolidated revenue was $337 billion in fiscal 2026 and $88.4 billion in the fourth quarter of fiscal 2026.

The company has introduced two new reporting segments. Specialty Pharmaceutical and Provider Services brings together capabilities spanning clinical-trial logistics, commercialization, specialty distribution, group purchasing and practice management. Pharmaceutical Distribution and Services covers distribution and related services for customers including pharmacies and health systems. Specialty distribution products also go into the latter segment.

In the earlier structure, U.S. Healthcare Solutions distributed medicines and other products to a range of providers, including specialists treating oncology and retina patients. International Healthcare Solutions supplied providers primarily in Europe and offered specialty transportation, logistics and life-sciences services. Beginning in fiscal 2026, some businesses being evaluated for strategic alternatives were grouped in Other. Cencora entered into agreements or completed divestitures for all the businesses in that group during the year.

Many U.S. brand-name purchasing and sales arrangements use the manufacturer’s wholesale acquisition cost as a reference price, although some customers buy at a negotiated contract price. Certain manufacturer agreements also have a price appreciation component. Cencora generally acts as a primary supplier to provider customers, while customer contracts and ongoing services support repeat business; contracts can expire, be terminated or be renewed on different terms.

Generic and biosimilar products have historically offered greater gross profit margin opportunities than brand-name products, although their lower prices reduce revenue growth. Cencora says its services for Part B biosimilars allow it to earn a higher margin.

Customers and how it sells

Cencora serves both healthcare providers and pharmaceutical manufacturers. Provider customers include hospitals, health systems, physician practices, mail-order pharmacies, independent community pharmacies, retail drugstore chains and veterinarians. Manufacturer customers include branded, generic and biotechnology drugmakers, as well as makers of over-the-counter products.

The company reaches customers through distribution centers and operations in the United States and selected global markets. Its U.S. sales force is organized with geographic and provider-specific focuses, while its international businesses have sales forces for their respective products and services. Electronic ordering, inventory replenishment and billing systems also connect the company with customers.

International pharmaceutical wholesale operations serve pharmacies, doctors, health centers and hospitals primarily in Europe. Cencora also has operations in Canada and specialty logistics operations across more than 50 countries.

Large customer relationships account for a substantial portion of sales. Walgreens and Boots were major customers, and Evernorth Health Services represented 13.0% of fiscal 2025 revenue. The top 10 customers, including governmental agencies and group purchasing organizations, represented approximately 66% of fiscal 2025 revenue. Cencora is the primary pharmaceutical distributor for Walgreens in the United States and Boots in the United Kingdom.

Suppliers and costs

Cencora obtains pharmaceuticals and other products from manufacturers rather than relying on a single named supplier. No manufacturer accounted for 10% or more of its purchases in fiscal 2025; the 10 largest suppliers accounted for approximately 57%. The company says losing a supplier could affect its business if alternative sources are unavailable, because it is committed to be the primary source of pharmaceutical products for a majority of its customers.

Product purchases are a principal cost. Manufacturer pricing practices, inventory quantities and product mix affect cost of goods sold. For U.S. brand-name products, the company’s purchase arrangements generally use wholesale acquisition cost as a reference price. Walgreens Boots Alliance Development GmbH also negotiates acquisition pricing with generic manufacturers on Cencora’s behalf.

Distribution, selling and administrative expenses include the costs of supporting distribution and other operations. Cencora invests in warehouse automation, information systems and cybersecurity. Its U.S. Healthcare Solutions gross profit margin was 2.72% in fiscal 2025; the acquisition of Retina Consultants of America increased that margin, while higher sales of lower-margin GLP-1 products partly offset the increase. In the fourth quarter of fiscal 2026, consolidated adjusted operating expenses were $2.3 billion, largely reflecting the acquisition of OneOncology.

Competitive position

Cencora competes in pharmaceutical distribution and related healthcare services. Its largest competitors include McKesson, Cardinal Health and UPS Logistics. In U.S. human health distribution, it competes directly with McKesson and Cardinal Health, as well as national generic and regional distributors. It also competes with manufacturers selling directly to customers, chain drugstores operating their own warehouses, specialty distributors, and packaging and healthcare technology companies.

Competition involves price, product offerings, delivery, credit terms, customer support and value-added services. Cencora’s U.S. distribution network includes a national distribution center that gives manufacturers a single shipping destination. Electronic systems support ordering, inventory replenishment and billing, while pharmacy programs and services give customers additional ways to work with the company.

Our reading: The distribution network and electronic systems provide a meaningful operational advantage because they connect product supply with customers’ ordering and inventory needs. Our reading: Those relationships do not eliminate competitive pressure, since customers can use other distributors or, in some cases, manage their own warehousing.

Cencora has also built specialty logistics, distribution and practice-management capabilities. Its specialty platform connects manufacturer services with support for physician providers, including research and administrative assistance. Our reading: The breadth of these services can make Cencora useful at several points in a drug’s journey to a patient, although the evidence does not establish a precise market share or guarantee that customers will keep all of those services with Cencora.

Growth opportunities

Cencora’s growth strategy centers on pharmaceutical distribution and services for providers and manufacturers, with particular investment in specialty medicines. In fiscal 2025, U.S. Healthcare Solutions revenue grew with higher unit volumes, including increased specialty product sales to health systems and physician practices and increased sales of GLP-1 products labeled for diabetes and/or weight loss. International growth included higher sales in European distribution.

Cencora believes research and development in biotechnology and other specialty drugs will create opportunities for its specialty business. It also views wider use of generic medicines and biosimilars as favorable for gross profit margin opportunities, even though their lower prices reduce revenue growth. The company says specialty biologics now account for more than 50% of pharmaceutical spending in the United States.

Acquisitions are another part of the strategy. Cencora acquired an 85% interest in Retina Consultants of America in January 2025 and completed its acquisition of OneOncology in February 2026. It has also agreed to acquire a majority interest in American Oncology Network. These businesses add to its services for specialty practices and pharmaceutical companies.

Cencora expects specialty distribution revenue to reach approximately $100 billion in fiscal 2027. It has introduced an operating model that brings specialty capabilities together under Specialty Pharmaceutical and Provider Services, alongside Pharmaceutical Distribution and Services. The company expects long-term operating income growth in the mid teens for the specialty segment and in the mid single digits for the distribution segment. These are company expectations, not guaranteed results.

Structural risks

• Customer concentration: Losing a key customer or group purchasing organization, or renewing a contract on less favorable terms, could hurt revenue and results. Changes in Walgreens and Boots’ operations or their relationship with Cencora could affect distribution and generic purchasing arrangements.
• Drug pricing: Manufacturer price changes affect purchasing and sales arrangements. Slower brand-name price increases or faster generic price deflation could adversely affect results; changes in drug pricing policies or direct-to-consumer models could also alter distribution economics.
• Acquisitions and divestitures: Acquired businesses may not achieve expected results, and integration can be more costly or time-consuming than expected. Divestitures can face delays, approval conditions or continuing obligations.
• Regulation and reimbursement: Pharmaceutical distribution is subject to licensing, controlled-substance and supply-chain requirements. Compliance can increase costs, and failures can disrupt operations; lower healthcare reimbursement can also affect customers’ ability to buy drugs.
• Systems and cybersecurity: Distribution depends on information systems for orders, inventory, billing and payments. System failures or cyberattacks involving Cencora or its partners could interrupt operations, expose data, increase costs or lead to litigation.
• Supply and logistics: Supplier losses can be disruptive if substitutes are unavailable. Cold-chain shipping, international operations, currency movements, tariffs and other disruptions can affect costs or product availability.

Bottom line

Our reading

Our reading: Cencora combines a pharmaceutical distribution business built around recurring customer supply needs with specialty services that connect manufacturers and healthcare providers. [item1] [call_prepared]

Its distribution relationships and infrastructure support the business, but large customer concentration, manufacturer pricing and the need to execute acquisitions and portfolio changes remain material exposures. [item1a] [item7] The newer specialty platform expands its activities beyond distribution while adding integration and regulatory demands. [call_prepared] [item1a]